Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (CANF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CANF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCan-Fite BioPharma Ltd. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 39.43% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2010 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -39.43% |
| 2024-12-31 | $0.00B | -$0.00B | -9.29% |
| 2023-12-31 | $0.00B | -$0.00B | -8.27% |
| 2022-12-31 | $0.00B | -$0.00B | -5.04% |
| 2021-12-31 | $0.00B | +$0.00B | +11.80% |
| 2020-12-31 | $0.00B | -$0.00B | -62.45% |
| 2019-12-31 | $0.00B | -$0.00B | -46.81% |
| 2018-12-31 | $0.00B | +$0.00B | +352.21% |
| 2017-12-31 | $0.00B | +$0.00B | +398.38% |
| 2016-12-31 | $0.00B | +$0.00B | +2.90% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Can-Fite BioPharma Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Can-Fite BioPharma Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Can-Fite BioPharma Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CANF revenue · 4 questionsCANF's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 39.43% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Can-Fite BioPharma Ltd. SEC filings · GAAP · Can-Fite BioPharma Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026